James Edgemond Sells 10,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction on Thursday, March 26th. The stock was sold at an average price of $535.90, for a total transaction of $5,359,000.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $10,115,648.40. This represents a 34.63% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

James Edgemond also recently made the following trade(s):

• On Monday, March 23rd, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $522.83 on Monday. The firm has a market cap of $22.92 billion, a P/E ratio of 18.74, a P/E/G ratio of 1.88 and a beta of 0.84. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $549.50. The business has a fifty day simple moving average of $495.95 and a 200 day simple moving average of $473.67.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The firm had revenue of $790.20 million for the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business’s revenue was up 7.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $6.19 EPS. As a group, equities research analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.

Analyst Ratings Changes

Several brokerages recently commented on UTHR. Royal Bank Of Canada upped their target price on United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Cantor Fitzgerald raised their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. Bank of America restated a “neutral” rating on shares of United Therapeutics in a research report on Wednesday, February 25th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Finally, Oppenheimer increased their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and an average target price of $549.91.

Institutional Investors Weigh In On United Therapeutics

Large investors have recently added to or reduced their stakes in the business. Avoro Capital Advisors LLC boosted its holdings in shares of United Therapeutics by 17.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after buying an additional 383,838 shares in the last quarter. Wellington Management Group LLP grew its position in shares of United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after buying an additional 1,042,711 shares during the period. AQR Capital Management LLC increased its stake in shares of United Therapeutics by 29.9% in the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock valued at $624,508,000 after acquiring an additional 295,221 shares in the last quarter. Invesco Ltd. increased its stake in shares of United Therapeutics by 90.2% in the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after acquiring an additional 419,588 shares in the last quarter. Finally, Janus Henderson Group PLC lifted its position in shares of United Therapeutics by 75.1% during the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock valued at $387,801,000 after acquiring an additional 341,383 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.